Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study on tolerability of injective allergoid immunotherapy for house dust mite allergy
2007-003058-26Phase 2Completed
- Sponsor
- Lofarma S.p.A.
- Start
- Oct 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Dermatophagoides injective allergoid in allergic rhinoconjunctivitis (ARC), allergic rhinitis (AR) and asthma, sponsored by Lofarma S.p.A. Primary endpoints: tolerability evaluation and safety evaluation. Started Oct 2007; status: completed.
02
Drugs
Dermatophagoides injective allergoid
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on 2007-003058-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003058-26.